Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Interest & Investment Income (2016 - 2023)

Gyre Therapeutics has reported Interest & Investment Income over the past 14 years, most recently at $47000.0 for Q3 2023.

  • Quarterly Interest & Investment Income fell 83.33% to $47000.0 in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $384000.0 through Sep 2023, down 19.16% year-over-year, with the annual reading at $717000.0 for FY2022, 1938.46% up from the prior year.
  • Interest & Investment Income was $47000.0 for Q3 2023 at Gyre Therapeutics, down from $73000.0 in the prior quarter.
  • Over five years, Interest & Investment Income peaked at $1.0 million in Q1 2020 and troughed at -$74000.0 in Q4 2021.
  • The 5-year median for Interest & Investment Income is $99000.0 (2022), against an average of $208000.0.
  • Year-over-year, Interest & Investment Income plummeted 98.33% in 2021 and then skyrocketed 3928.57% in 2022.
  • A 5-year view of Interest & Investment Income shows it stood at $489000.0 in 2019, then crashed by 113.5% to -$66000.0 in 2020, then fell by 12.12% to -$74000.0 in 2021, then skyrocketed by 327.03% to $168000.0 in 2022, then tumbled by 72.02% to $47000.0 in 2023.
  • Per Business Quant, the three most recent readings for GYRE's Interest & Investment Income are $47000.0 (Q3 2023), $73000.0 (Q2 2023), and $96000.0 (Q1 2023).